Kornimate/medical-research-clean huggingface dataset:
urinary diversion during robotic assisted radical cystectomy in patients with bladder cancer

Conditions: Recurrent Bladder Cancer; Stage 0 Bladder Cancer; Stage I Bladder Cancer; Stage II Bladder Cancer; Urinary Complications

Summary: this randomized clinical trial studies intracorporeal or extracorporeal urinary diversion during robotic assisted radical cystectomy in reducing complications in patients with bladder cancer. radical cystectomy is surgery to remove the entire bladder as well as nearby tissues and organs. after the bladder is removed, urinary diversion (a surgical procedure to make a new way for urine to leave the body) is performed. it is not yet known whether intracorporeal (within the body) or extracorporeal (outside of the body) urinary diversion is a better method in patients with bladder cancer undergoing robotic assisted radical cystectomy.

primary objectives: i. to compare perioperative outcomes and complications after robotic assisted radical cystectomy (rarc) with intracorporeal urinary diversion (iud) and rarc with extracorporeal urinary diversion (eud) in a prospective randomized fashion. secondary objectives: i. time to passage of flatus. ii. analgesic requirement (narcotic use). iii. hospital length of stay. iv. total operating time. v. estimated blood loss. vi. readmission rate. vii. bladder cancer index questionnaire. viii. ureteral strictures. ix. stomal stenosis. x. disease recurrence. xi. secondary procedures. outline: patients are randomized to 1 of 2 treatment arms. arm i: patients undergo rarc with iud. arm ii: patients undergo rarc with eud. after completion of study treatment, patients are followed up within 90 days and then for 2-5 years.

Eligibility criteria:
inclusion criteria: * grade g1 - g3 bladder cancer * t stage: ctis - t2 * n0 * m0 * american society of anesthesiologists (asa) \< 4 * informed consent * eastern cooperative oncology group (ecog) performance status 2 or better * hemoglobin (hgb) \> 8.0 g/dl * white blood cell (wbc) \> 2.0 k/ul * platelets \> 50,000 * creatinine \< 3.0 x upper limit of normal (uln) * aspartate aminotransferase (ast) \< 5.0 x uln * alanine transaminase (alt) \< 5.0 x uln exclusion criteria: * patient unsuitable for or refusing radical cystectomy * t stage ≥ t3 (mass extending outside the bladder) * gross nodal or metastatic disease at presentation (≥ n1, m1) * prior pelvic radiation * prior open or laparoscopic/robotic bladder or prostate surgery * prior colorectal surgery or history of inflammatory bowel disease * body mass index (bmi) ≥ 40 * ecog performance status 3 or worse * history of coagulopathy or bleeding disorders * chronic steroid use * patients with end stage renal disease (esrd) and/or on dialysis
the effect of fish oil supplementation on endothelial function, heart rate variability and intimal media thickness of patients with coronary artery disease

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to investigate whether there is a difference in endothelial function, heart rate variability and carotid intimal media thickness in patients with coronary artery disease who are receiving fish oil therapy. one hundred patients with established coronary artery disease by coronary angiography will undergo randomization for enrollment in the study. baseline evaluation will include assessment of brachial artery endothelial function, heart rate variability and carotid intimal media thickness. evaluation of the endothelial function of the brachial artery will be elucidated by inflation of a blood pressure cuff around the arm for five minutes and measuring blood vessel dynamics after release of the cuff. heart rate variability will be evaluated by 24 hour holter monitoring and analysis by standard protocol. carotid intimal media thickness will be evaluated by ultrasound measurements guided by predetermined protocol. patients will then be randomized to a highly purified fish oil, omacor, 1 gram twice a day or placebo. brachial artery ultrasound and holter monitoring will be repeated at 2 months. carotid ultrasound will be repeated at the end of the study at 12 months.


Eligibility criteria:
inclusion criteria: 1. established coronary artery disease as determined by coronary angiography within the last 5 years demonstrating at least 50% stenosis in one of the major coronary vessels 2. age \>18 and \<75. exclusion criteria: 1. baseline fish oil intake ≥1g/day or fish intake \>100g/day 2. need for urgent or emergent cabg 3. contraindication for plavix, aspirin or statin 4. gastrointestinal malabsorption syndrome 5. pregnancy 6. oral contraceptive use 7. ejection fraction \<40% 8. underlying atrial or ventricular arrhythmia 9. history of rheumatoid arthritis

Keywords: omacor fish oil omega 3 fatty acids coronary artery disease endothelial function heart rate variability carotid intimal media thickness qt dispersion
effect of hyaluronic acid on perimplantitis

Conditions: Peri-Implantitis

Summary: the effect of the hyaluronic acid treatment on peri-implantitis has not been tested. the aim was to analyze the effect of a hyaluronic acid-containing gel on the clinical variables and the expression of biochemical inflammatory markers in the crevicular fluid of implants receiving perimplantitis treatment.

the aim was to analyze the effect of a hyaluronic acid-containing gel on the clinical variables and the expression of biochemical inflammatory markers in the crevicular fluid of implants receiving perimplantitis treatment. a randomized, controlled, double-blind clinical trial was designed on 100 perimplantitis affected implants placed in 61 subjects. inclusion criteria were implants with at least 1 year of functional loading and with diagnosis of perimplantitis following the criteria from the association of dental implantology. all implant received perimplantitis treatment. each patient was randomly assigned to receive a gel containing 0.8% ha (test group), a gel without ha (placebo group) or no gel treatment (control group). after a first gel application at baseline, test and placebo patients performed gel applications at home 3 times/day for 45 days. clinical variables of each implant were recorded at baseline, 45 and 90 days (probing depth, attachment loss, bleeding). intraoral radiographs of each implants were performed to measure marginal bone level. peri-implant crevicular fluid was collected from each implant at baseline and after 45 days of treatment, to assess il-1β and tnfα levels by elisa technique. clustering analysis, considering multiple implants within each patient, was performed.

Eligibility criteria:
inclusion criteria: * implants with at least one year of functional load. * implants diagnosed with peri-implantitis according to the criteria of the association of dental implantology. exclusion criteria: * previous peri-implantitis treatment. * pregnancy or breast-feeding. * neoplastic disease. * antibiotic treatment during the previous month.

Keywords: peri-implantitis dental implants hyaluronic acid clinical trial
study of fibrogen (fg)-3019 in subjects with type 2 diabetes mellitus and kidney disease on acei and/or arb therapy

Conditions: Type 2 Diabetes Mellitus; Diabetic Nephropathy; Diabetic Kidney Disease

Summary: the purpose of this study is to evaluate the effect of fg-3019 on diabetic kidney disease or diabetic nephropathy.

the primary objective of this study is to assess the effect of fg-3019 on proteinuria as assessed by urinary albumin/creatinine ratio (acr).

Eligibility criteria:
key inclusion criteria: 1. signed written informed consent 2. males and females 18-75 years of age, inclusive 3. diagnosis of type 2 diabetes mellitus according to american diabetes association (ada) criteria 4. 24-hour urinary acr 200-3000 mg/g, inclusive, on two occasions during screening at least 2 days apart 5. estimated glomerular filtration rate (egfr) (by mdrd equation) \>20 ml/min/1.73 m2 6. mean systolic blood pressure less than or equal to 150 mmhg and a mean diastolic blood pressure less than or equal to 95 mmhg 7. receiving acei and/or arb therapy at an unchanged dose at or above the minimum trial dosage for at least 3 months prior to the first screening visit and willing to maintain these doses throughout the treatment period key exclusion criteria: 1. females who are pregnant or breast feeding 2. organ transplant recipient, history of dialysis, or known non-diabetic renal disease other than benign cysts or anatomical variants 3. history of new york heart association class iii/iv heart failure 4. screening electrocardiogram showing acute and/or clinically significant findings including but not limited to st depression 5. history of any of the following events within 3 months prior to screening: coronary artery bypass graft, cerebrovascular accident, myocardial infarction, transient ischemic attack, unstable angina, uncontrolled cardiac arrhythmia, atrial fibrillation, percutaneous coronary intervention, or vascular stent placement 6. history of anaphylactic or systemic allergic reaction to human, humanized, chimeric, or murine monoclonal antibodies 7. aspartate aminotransferase (ast) and/or alanine aminotransferase (alt) \>2.5 times the upper limit of normal; direct bilirubin above the upper limit of normal, or \>2.5 times the upper limit of normal in cases of documented gilbert's syndrome 8. hemoglobin \<10 g/dl 9. hemoglobin a1c (hba1c) \>9 % 10. low density lipoprotein (ldl) \>130 mg/dl
evaluating the efficacy of structured exercise interventions in alleviating aromatase inhibitor-induced arthralgia in breast cancer survivors: a pilot study protocol

Conditions: Musculoskeletal Symptoms; Breast Cancer; Endocrine Therapy; Aromatase Inhibitors

Summary: endocrine therapy represents a foundational approach for managing hormone receptor-positive breast cancer, with treatment typically spanning 5 to 10 years. although its clinical efficacy is well-established, medications like aromatase inhibitors frequently result in musculoskeletal (ms) complications, such as joint discomfort, stiffness (especially in the morning), carpal tunnel syndrome, tenosynovitis, myalgia, and reduced muscle strength. these issues, which can manifest intermittently or persistently, impact both central joints (spine, hips, shoulders) and peripheral ones (elbows, wrists, knees, feet), thereby substantially diminishing patients' quality of life (qol). evidence suggests that physical activity can mitigate these symptoms; however, adherence to exercise routines remains insufficient. moreover, there is no agreement regarding the most effective type, intensity, or duration of exercise, and standardized guidelines are absent. acknowledging the need for exercise as a sustainable habit, this research aims to design a home-based rehabilitation program customized for individuals undergoing endocrine therapy.


Eligibility criteria:
inclusion criteria:1. pathologically confirmed hormone receptor-positive breast cancer (stage i, ii, iii). 2. initiation of treatment with aromatase inhibitors (e.g., anastrozole, letrozole, exemestane). 3. postmenopausal women, including those with surgically induced menopause. 4. clear consciousness, no cognitive or communication impairments, and able to comply with the intervention. 5. informed consent obtained, with voluntary participation in the study. 6. bone and joint symptoms with a brief pain inventory (bpi) score of ≥3, or presence of at least one of the following risk factors: elevated bone turnover markers, reduced vitamin d levels, increased inflammatory cytokines, elevated c-reactive protein, or elevated rheumatoid factor. 7. not participating in any physical therapy or exercise-based interventions that may interfere with this study. - exclusion criteria: - 1. recurrence of breast cancer or distant metastasis. 2. presence of other malignancies. 3. diagnosed rheumatoid arthritis, bone and joint trauma, or other severe bone and joint diseases. 4. bone mineral density t-score \<-2.5. 5. presence of absolute contraindications to exercise.
one-month dapt in cabg patients

Conditions: Chronic Coronary Disease

Summary: the purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.

a multinational, randomized trial to evaluate the effect of one-month of ticagrelor plus low-dose aspirin, versus low-dose aspirin alone, on the incidence of death, myocardial infarction, stroke, repeat revascularization and graft failure in patients with chronic coronary disease undergoing coronary artery bypass grafting.

Eligibility criteria:
inclusion criteria: * age ≥18 years * elective first-time cabg with use of ≥1 saphenous vein graft; * ability to sign informed consent and comply with all study procedures, including follow-up for at least 5 years. exclusion criteria: * any indication for dual antiplatelet therapy, including * acute/recent (within 1 year) acs (nste-acs or stemi) * recent pci requiring continuation of dual antiplatelet therapy after cabg * current or anticipated use of oral anticoagulation; * paroxysmal, persistent or permanent atrial fibrillation; * any concomitant cardiac or non-cardiac procedure; * planned cardiac or non-cardiac surgery within one year; * preoperative end-organ dysfunction (dialysis, moderate to severe liver failure, respiratory failure), cancer or other non-cardiac comorbidity with a life expectancy \<5 years; * inability to use the saphenous vein; * contraindications to the use of aspirin; * contraindications to the use of ticagrelor, including * known hypersensitivity to ticagrelor * active pathological bleeding (including, but not limited to gastrointestinal or intracranial bleeding) * history of intracranial hemorrhage * concomitant therapy with strong cyp3a4 inhibitors (eg ketoconazole, clarithromycin, nefazodone, ritonavir, atazanavir) * inability to undergo coronary computed tomographic angiography (ccta); * participating in another investigational device or drug study; * women of childbearing potential * any major perioperative complication including, but not limited to, stroke, tia, mi, cabg-related bleeding (barc type 4), sepsis.
pk//pd/tolerability study of da-1229(evogliptin) in renal impaired patients

Conditions: Renal Impairment

Summary: this is a clinical study to investigate the pharmacokinetics/pharmacodynamics and tolerability of da-1229(evogliptin) tabletin renal impaired patients.


Eligibility criteria:
inclusion criteria: * age between 20 and 70 * weights between 50 and 90kg(female : 40 and 90kg) * volunteer who totally understands the progress of this clinical trials, makes decision by his free will, and signed a consent form to follow the progress * stable results of estimated gfr in 4 months recently exclusion criteria: * volunteer who has past or present history of any diseases following below.(liver including hepatitis virus carrier, kidney, neurology, immunology, pulmonary, endocrine, hematooncology, cardiology, mental disorder) * volunteer who had drug(dpp-4 inhibitor) hypersensitivity reaction * volunteer who already participated in other trials in 2 months * volunteer who had whole blood donation in 2 months, or component blood donation in 1 months or transfusion

Keywords: patients
response shift in patient expectations and functional outcome

Conditions: Spinal Injuries

Summary: the purpose of this study is to evaluate the results of elective lumbar spinal surgery as it relates to shifting patient expectations for outcome. patients undergoing elective posterior spinal surgery for degenerative conditions of the spine at swchsc will be evaluated.


Eligibility criteria:
inclusion criteria: * all patients with a diagnosis of a degenerative condition of the lumbar spine undergoing posterior lumbar spinal surgery at sunnybrook and women's college health sciences centre * patients who have had previous lumbar surgery exclusion criteria: * traumatic or neoplastic surgical conditions of the lumbar spine
patient decision aid in supporting decision-making about when to start or stop new drugs, join clinical trials, or continue active surveillance in patients with medullary thyroid cancer and their caregivers

Conditions: Thyroid Gland Medullary Carcinoma

Summary: this trial develops and studies how well a patient decision aid works in supporting decision-making about when to start or stop new drugs, join clinical trials, or continue active cancer monitoring for patients with medullary thyroid cancer and their caregivers. developing a patient decision aid may help patients with medullary thyroid cancer make well-informed decisions about their cancer care and be able to discuss their preferences with their doctors.

primary objectives: i. to assess patient/survivor, caregiver/family member, and provider decision-making needs. ii. to design and develop an initial patient decision aid prototype. iii. to pilot test its acceptability. iv. to evaluate the acceptability and usability of the decision aid prototype from patients/survivors, caregivers and providers in a real world environment. outline: participants use decision aid and complete questionnaire.

Eligibility criteria:
inclusion criteria: * aged 18 years old or older * have or will face(d) this decision, including: patient/survivor - who has medullary thyroid carcinoma, as determined by a clinician or documented in the genetics of endocrine neoplasia registry or sporadic (medullary thyroid carcinoma) mtc database; caregiver/family member - of patient/survivor who has medullary thyroid carcinoma, as nominated by the patient/survivor; and provider - who treats patients/survivors who have medullary thyroid carcinoma, as described above * able to speak, read, and write english * pregnant patients are included exclusion criteria: --individuals with cognitive or psychological impairment (e.g., depression, anxiety, severe mental illness; as documented in the registry)
a clinical study to evaluate the safety and efficacy of the combination of aliskiren and valsartan in hypertensive non responders patients

Conditions: Hypertension

Summary: to evaluate the blood pressure lowering effect and safety of the triple combination aliskiren / valsartan / hctz (300/320/25 mg) in patients with essential hypertension not adequately responsive to hctz 25 mg


Eligibility criteria:
inclusion criteria * patients with essential hypertension * patients who are eligible and able to participate in the study exclusion criteria * severe hypertension * history or evidence of a secondary form of hypertension other protocol-defined exclusion criteria may apply.

Keywords: hypertension, aliskiren, blood pressure, valsartan, hctz
changes of dendritic cells in acute lung injury

Conditions: Acute Lung Injury

Summary: to observe changes of circulating and tissue dendritic cells in acute lung injury,including invasive aspergillosis pneumonia

change of circulating and tissular dendritic cells of patients with acute lung injury was still unclear, we used a flow cytometry-based assay to quantify circulating and tissular dcs and their hla-dr surface expression at the time of diagnosis and during the first week of evolution in patients with acute lung injury, and healthy people as controls.

Eligibility criteria:
inclusion criteria: * sepsis induced acute lung injury exclusion criteria: * younger than 18-year-old * pregnancy * cancer or organ transplant * asthma * copd * heart failure

Keywords: dendritic cell
prevalence of non-carious cervical lesions, associated risk indicators and salivary assessment among middle adulthood patients.

Conditions: Non-carious Cervical Lesions

Summary: the aim of this study is to describe the prevalence of non-carious cervical lesions in middle adulthood patients attending the cairo university dental educational hospital and to analyze the distribution of lesions by gender and age, tooth functional group, jaw, arch side and tooth surface. moreover, to explore the associated risk indicators of the lesions as well as the flow rate and ph of saliva, as one of the potential etiological factors, will be assessed.

dental patients will be recruited from diagnostic central clinic at the cairo university dental educational hospital. oral examination will be done, the full aim of the study will be explained to the patient, and patient acceptance is a must. the questionnaire will be filled by patients including age, gender, occupation, education, place of residence, toothbrushing: included frequency, method, intensity, hardness and duration, biting and chewing habits, medical history \[related to gastrointestinal problems such as belching, heartburn, vomiting, gastro-oesophageal reflux (ger), peptic ulcer disease\], eating disorders (anorexia, bulimia), medication list, frequency of consuming acidic food and fruits, carbonated beverages and alcohol and smoking status. salivary assessment regarding flow rate and ph for a subgroup diagnosed with non-carious cervical lesions.

Eligibility criteria:
inclusion criteria: 1. patients whose age between 41-60 years old. 2. patient consulting in the outpatient clinic 3. provide informed consent. 4. males \& females 5. egyptian exclusion criteria: 1. patients under or over this age group. 2. refuse to participate in the study. 3. wearing orthodontic appliance. 4. the presence of trismus.

Keywords: patient-related risk factors
prospective study of bk virus disease after allogeneic hematopoietic-cell transplantation: defining bk disease's natural history, clinical spectrum, immunology, and outcomes

Conditions: BK Virus Infection

Summary: this research study is evaluating the reactivation of bk virus in patients who have undergone allogeneic hematopoietic-cell transplantation.

every year, more than 25,000 patients worldwide receive lifesaving bone marrow transplantations with hematopoietic-cells from another person. it is estimated that over 75% of these patients will develop an infectious complication, of which approximately one third can be life-threatening. a significant proportion of these infections are caused by opportunistic viruses, such as bk virus. this virus establishes latent infection in most individuals, but does not normally cause disease. it can reactivate after hematopoietic-cell transplantation and represents the second most common viral infection in this patient population. bk virus is associated with kidney failure and a decreased chance of survival after hematopoietic-cell transplantation. there are no effective antiviral treatments for this disease. despite being the second most common cause of clinical disease hematopoietic-cell transplantation, very little is known about this virus. to address this knowledge gap, the investigators aim to study patients with confirmed bk virus disease post allogeneic hematopoietic-cell transplantation. as part of this study, regular urine and blood tests will be done to understand how the virus behaves over time and which organs it affects. blood and urine samples will also be obtained to study how the immune system rebuilds itself after hematopoietic-cell transplantation. finally, an ultrasound of the kidneys and the bladder will be done to evaluate for any presence of disease in these organs.

Eligibility criteria:
inclusion criteria: * adult ≥18 years old * all adult patients who undergo allo-hct will be eligible for the study, regardless of age, underlying disease, conditioning regimen, or gvhd prophylaxis regimen exclusion criteria: * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * pregnant women * prisoners

Keywords: bk virus bk polyomavirus hematopoietic-cell transplantation